Target |
SSI Pathogen |
Total Plasma |
Muscle |
Subcutaneous |
MS |
CPB+DHCA |
MS |
CPB+DHCA |
MS |
CPB+DHCA |
2 μg/mL |
MSSA |
100%
(97-100%) |
100%
(100-100%) |
100%
(100-100%) |
100%
(100-100%) |
100%
(96-100%) |
100%
(100-100%) |
16 μg/mL |
E. coliK. pneumoniae |
48%
(28-76%) |
100%
(100-100%) |
67%
(60-73%) |
78%
(55-99%) |
60%
(38-82%) |
79%
(56-100%) |
32 μg/mL |
S. epidermidis
Enterobacter sp. |
31%
(15-46%) |
99%
(98-100%) |
26%
(23-29%) |
18%
(12-41%) |
30%
(19-55%) |
26%
(12-41%) |
Each concentration target represents an estimated MIC90 of bacteria [31] potentially susceptible to cefazolin and known to cause SSIs in pediatric cardiac surgical patients. Abbreviations: MS = median sternotomy; CPB+DHCA = cardiopulmonary bypass with deep hypothermic circulatory arrest; μg = microgram; mL = milliliter; min = minutes; MSSA = methicillin sensitive Staphylococcus aureus; E. = Escherichia; K. = Klebsiella; S. = Staphylococcus; sp. = species. |
|